Camlin Fine Sciences Q1 FY27 Results: Consolidated Loss Narrows to ₹329.66 Million
Camlin Fine Sciences reported consolidated revenue of ₹5,198.79 million for Q1 FY27. The consolidated net loss narrowed to ₹317.06 million. Standalone revenue was ₹2,224.86 million with a net loss of ₹123.12 million for the quarter ended June 30, 2026. The Board approved these results on August 11, 2026.
The announcement of quarterly financial results is a material event for investors. While the loss has narrowed, it is still a significant factor affecting the company's financial health and investor sentiment.
The company reported a narrowed consolidated loss, which is a positive sign, but the standalone results also show a loss. The overall financial performance is mixed, leading to a neutral sentiment.
Camlin Fine Sciences Limited announced its un-audited financial results for the quarter ended June 30, 2026, during its Board Meeting held on August 11, 2026. The company reported consolidated revenue from operations of ₹5,198.79 million (₹519.88 crore) for the quarter.
The consolidated net loss for the quarter attributable to owners of the company was ₹317.06 million (₹31.71 crore), a narrowing from a profit of ₹882.02 million (₹88.20 crore) in the previous quarter (ended March 31, 2026) and a loss of ₹99.61 million (₹9.96 crore) in the same quarter last year (ended June 30, 2025). Total comprehensive income attributable to owners of the company for the quarter was a loss of ₹139.58 million (₹13.96 crore).
On a standalone basis, the company reported revenue from operations of ₹2,224.86 million (₹222.49 crore) for the quarter. The standalone net loss for the quarter was ₹123.12 million (₹12.31 crore), compared to a loss of ₹56.49 million (₹5.65 crore) in the previous quarter and a loss of ₹106.81 million (₹10.68 crore) in the corresponding quarter last year. Total comprehensive income for the standalone results was a loss of ₹86.28 million (₹8.63 crore).
The report also details segment-wise performance, with Specialty Ingredients, Aroma, and Performance Chemicals & Others as the reporting segments. The company's Board Meeting commenced at 2:00 p.m. (IST) and concluded at 3:35 p.m. (IST).
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.